Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion in Depression
NCT02104128Completed
- Sponsor
- University of Oxford
- Start
- Jan 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of bupropion in major depressive disorder (MDD) (2 arms), sponsored by University of Oxford. Primary endpoint: Change in haemodynamic (BOLD signal) response at 2 weeks. Started Jan 2014; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02104128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104128.